The global antibiotic resistance market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to increasing prevalence of antibiotic-resistant infections and the emergence of multi-drug resistant pathogens.
Antibiotic resistance (ABR) occurs as a result of excessive and uncontrolled antibiotic use. Most antibiotics are sold as over-the-counter medications, and many people use them without a doctor's prescription. Furthermore, most physicians, particularly in developing countries, prescribe antibiotics for viral diseases without properly diagnosing the disease. All of these factors contribute to the emergence of antibiotic resistance.
Pharmaceutical giants such as GlaxoSmithKline, Johnson & Johnson, Novartis, and Sanofi are at the vanguard of the global pharmaceutical industry, yet they're less engaged in antibiotic clinical development. This is due to the slow growth in revenues for marketed medications and low returns on investments. For instance, Novartis, recently terminated all intentions to continue research and development for its antibiotic medications. On the other side, various biotech companies, such as Melinta Therapeutics, Achaogen, and Nabriva Therapeutics, have taken on the task of discovering antibiotic resistance medicines. In mature markets, foreign companies’ involvement acts as a stimulus to the market. Biotechnology companies are receiving financial assistance from organizations such as BARDA to complete early-stage development of innovative antibiotic-resistant illness medicines.
Manufacturers seek the designation of Qualified Infectious Disease Product (QIDP), which speeds up the clinical evaluation process and extends the exclusivity period for new generation antibiotics with high therapeutic value. The Generating Antibiotic Incentives Now (GAIN) Act, which was passed in 2012 as an addition to the US Food and Drug Administration Safety and Innovation Act, established the QIDP classification. The bill intends to encourage the development of novel treatments to combat the rising prevalence and severity of antibiotic-resistant illnesses.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of infectious diseases is expected to boost the market growth during the forecast period.
- Growing demand for novel therapies is projected to spur the market expansion in the coming years.
- Lack of trained personnel and stringent safety regulations are expected to hamper the market growth.
- Effective treatment is either unavailable or unaffordable, which can impede the market expansion.
- Rising investment in the R&D activities by biopharmaceutical companies are anticipated to create lucrative opportunities in the projected timeline.
Scope of the Report
The report on the global antibiotic resistance market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Antibiotic Resistance Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Diseases (Complicated Urinary Tract Infection, Complicated Intra-Abdominal Infections, Blood Stream Infections, Clostridium difficile Infections, Acute Bacterial Skin and Skin Structure Infections, Hospital Acquired Bacterial Pneumonia/Ventilator, and Community Acquired Bacterial Pneumonia), Pathogen (Acinetobacter baumannii (Carbapenem-resistant and ESBL-producing), Pseudomonas aeruginosa (Carbapenem-resistant), Staphylococcus Aureus (Methicillin-resistant), E. coli/K. pneumoniae (Carbapenem-resistant), Streptococcus pneumoniae (Penicillin-Non-Susceptible), Clostridium difficile (Cephalosporin-resistant and Tetracycline-resistant), Enterococcus faecium (Vancomycin-resistant) and Haemophilus Influenzae (Ampicillin-resistant)), Drug Classes (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Pfizer, Merck, Allergan, and Melinta Therapeutics
Market Segment Insights
Complicated Urinary Tract Infection segment is projected to constitute a key market share
Based on diseases, the antibiotic resistance market is segregated into complicated urinary tract infection, complicated intra-abdominal infections, blood stream infections, clostridium difficile infections, acute bacterial skin and skin structure infections, hospital acquired bacterial pneumonia/ventilator, and community acquired bacterial pneumonia. The complicated urinary tract segment is expected to account for a key market share owing to high treatment cost and limited treatment alternatives for Gram-negative pathogens, which account for majority of infection cases. Limited access to recently approved brand therapies such as Allergan's Avycaz, Merck's Zerbaxa, and Melinta Therapeutics' Vabomere due to a lack of low-cost treatment options for Gram-negative infections is driving the growth of the market segment.
Gram-positive bacteria are resistant to antibiotics, which then increases the number of infections, in terms of volume. However, the overall cost of therapy is lesser as compared to Gram-negative infections due to the availability of various treatment choices, including branded and generic medications. MRSA dominated the market share among Gram-positive infections, as it was the principal causal pathogen for the rising ABSSSI burden over the world.
Acinetobacter baumannii (carbapenem-resistant) segment is expected to grow at a robust pace
On the basis of pathogens, the antibiotic resistance market is divided into Acinetobacter baumannii (carbapenem-resistant), Pseudomonas aeruginosa (carbapenem-resistant), Staphylococcus aureus (methicillin-resistant), E. coli/k. Pneumoniae (carbapenem-resistant), Streptococcus pneumoniae (penicillin-non-susceptible), Clostridium difficile (cephalosporin-resistant, tetracycline-resistant), Enterococcus faecium (vancomycin-resistant), and Haemophilus influenzae (ampicillin-resistant).The Acinetobacter baumannii (carbapenem-resistant segment) is expected to account for a significant market share during the forecast period. The extreme significant resistance to current treatment options, these infections constitute a therapy challenge for doctors. Although these infections are less common than Gram-positive pathogens in terms of number of cases, they have a high financial burden since physicians are increasingly turning to innovative antibiotics, such as Allergan's Avycaz and Melinta Therapeutics' Vabomere.
Lipoglycopeptides segment is anticipated to register a substantial CAGR
Based on drug classes, the antibiotic resistance market is segregated into oxazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination, and others. The lipoglycopeptides segment is expected to register a substantial CAGR during the forecast period. On the other hand, the combination treatments segment, which includes fixed dose combinations of beta lactams and beta lactamase inhibitors, is expected to increase grow at a healthy rate in the projected timeline. The segment's growth is fueled by the high use of these medications for Gram-negative infections.
Europe is anticipated to dominate the market
On the basis of regions, the antibiotic resistance market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth is attributed to growing number of antibiotic-resistant infections. Greece, Italy, and Portugal were listed as the top three antibiotic consumers in the world among OECD countries, contributing to rising antibiotic resistance in the region. In terms of revenue, North America accounted for a large market share. The regional market expansion is being aided by a slew of new medicine launches and hefty treatment costs. During the forecast period, the market in the US is expected to contribute a major revenue to the region, as IDSA encourages the treatment of CDI, which increases the demand for innovative medicines.
Segments Covered in the Report
The global antibiotic resistance market has been segmented on the basis of
- Complicated Urinary Tract Infection
- Complicated Intra-abdominal Infections
- Blood Stream Infections
- Clostridium difficile infections
- Acute Bacterial Skin and Skin Structure Infections
- Hospital Acquired Bacterial Pneumonia/Ventilator
- Community Acquired Bacterial Pneumonia
- Acinetobacter baumannii (Carbapenem-resistant)
- Pseudomonas aeruginosa (Carbapenem-resistant)
- Staphylococcus Aureus (Methicillin-resistant)
- E. coli/K. pneumoniae (Carbapenem-resistant)
- Streptococcus pneumoniae (Penicillin-Non-Susceptible)
- Clostridium difficile (Cephalosporin-resistant and Tetracycline- resistant)
- Enterococcus faecium (Vancomycin-resistant)
- Haemophilus Influenzae (Ampicillin-resistant)
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Melinta Therapeutics
Key players competing in the antibiotic resistance market include Pfizer, Merck, Allergan, and Melinta Therapeutics.
Smaller entrants with novel antibiotics are being acquired by large pharmaceutical giants. For instance, Pfizer acquired Astra Zeneca's marketed medications, Zavicefta and Zinforo, as well as late-stage antibiotics, ATM-AVI, resulting in a larger antibiotic portfolio. Moreover, players in the industry uses indication extension and regional growth tactics to increase the market share.